Randomized Controlled Trial Comparing Slow-freezing to Vitrification of Oocytes
Information source: Samuel Lunenfeld Research Institute, Mount Sinai Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Infertility
Intervention: slow-freeze (Procedure); vitrification (Procedure)
Phase: N/A
Status: Terminated
Sponsored by: Samuel Lunenfeld Research Institute, Mount Sinai Hospital Official(s) and/or principal investigator(s): Ellen M Greenblatt, MD, FRCS(C), Study Director, Affiliation: Mount Sinai Hospital, Canada
Summary
Preservation of fertility is limited. Current methods include embryo cryopreservation and
while still experimental, ovarian cryopreservation. In single women who are at risk for
infertility secondary to cancer or couples who have ethical reasons to avoid embryo
cryopreservation, oocyte cryopreservation is an alternative Purpose of study is to compare
slow freeze to vitrification of human oocytes. Successful cryopreservation and subsequent
thawing programs are characterized by avoiding ice crystal formation. Vitrification, newer
alternative to slow freeze method, process by which water is prevented from forming ice.
Our hypothesis is that higher survival rate per oocyte is to be expected in the
vitrification group.
Clinical Details
Official title: Cryopreservation of Oocytes: A Randomized Controlled Trial Comparing Slow-freezing to Vitrification
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: post-thaw oocyte survival rate
Secondary outcome: fertilization ratecleavage embryo development implantation rate ongoing pregnancy
Detailed description:
Although several reviews of smaller studies of cryoprotectant methodology exist randomized
controlled trials,comparing slow-freeze-rapid-thaw procedure to vitrification of oocytes,
are not available. The purpose of this study is to compare these two methods of oocyte
cryopreservation in human oocytes.
Eligibility
Minimum age: 18 Years.
Maximum age: 37 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- 14 or more oocytes at ovum pick up
- age < 38
- bmi < 30
Exclusion Criteria:
-
Locations and Contacts
Mount Sinai Hospital, Toronto, Ontario M5G 1Z5, Canada
Additional Information
Related publications: Gook DA, Edgar DH. Human oocyte cryopreservation. Hum Reprod Update. 2007 Nov-Dec;13(6):591-605. Epub 2007 Sep 10. Review. Porcu E, Venturoli S. Progress with oocyte cryopreservation. Curr Opin Obstet Gynecol. 2006 Jun;18(3):273-9. Review. Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril. 2006 Jul;86(1):70-80. Jain JK, Paulson RJ. Oocyte cryopreservation. Fertil Steril. 2006 Oct;86(4 Suppl):1037-46. Review. Byrne J, Fears TR, Gail MH, Pee D, Connelly RR, Austin DF, Holmes GF, Holmes FF, Latourette HB, Meigs JW, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol. 1992 Mar;166(3):788-93. Falcone T, Attaran M, Bedaiwy MA, Goldberg JM. Ovarian function preservation in the cancer patient. Fertil Steril. 2004 Feb;81(2):243-57. Review. Porcu E, Fabbri R, Damiano G, Giunchi S, Fratto R, Ciotti PM, Venturoli S, Flamigni C. Clinical experience and applications of oocyte cryopreservation. Mol Cell Endocrinol. 2000 Nov 27;169(1-2):33-7. Review. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist. 2006 May;11(5):422-34. Review. Yoon TK, Kim TJ, Park SE, Hong SW, Ko JJ, Chung HM, Cha KY. Live births after vitrification of oocytes in a stimulated in vitro fertilization-embryo transfer program. Fertil Steril. 2003 Jun;79(6):1323-6.
Starting date: August 2008
Last updated: January 6, 2014
|